Glaukos CORP 10-Q quarterly reports

Glaukos Corporation reported a significant 50% increase in net sales for the second quarter of 2026, reaching $185.6 million, primarily fueled by strong performance of its iDose TR product.

Glaukos Corporation reported a 38% increase in net sales for Q3 2025, driven by strong iDose TR performance and the recent FDA approval of Epioxa, despite ongoing reimbursement challenges and a net loss.

Glaukos Corporation reported a significant reduction in net loss for the second quarter and first half of 2025, driven by robust sales growth in glaucoma products, particularly iDose TR, and improved gross margins.

Glaukos Corp's Q1 2025 revenue increased by 25% year-over-year, driven by iDose TR sales, but the company still reported a net loss.

Glaukos Corporation's Q3 2024 results show a 24% increase in revenue compared to the same period last year, driven by growth in glaucoma and corneal health product sales.

Glaukos Corporation's Q2 2024 results show a 19% increase in net sales, driven by glaucoma product growth and the launch of iDose TR, despite a net loss of $50.5 million.

Glaukos Corporation's first quarter 2024 results show a 16% increase in net sales, driven by the launch of iDose TR and growth in glaucoma product sales, despite a net loss of $40.8 million.